Welcome to our dedicated page for Xenon Pharmaceut news (Ticker: XENE), a resource for investors and traders seeking the latest updates and insights on Xenon Pharmaceut stock.
Xenon Pharmaceuticals Inc. (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company whose news flow centers on clinical progress, scientific data, and corporate developments in neurology and psychiatry. The company is advancing azetukalner, a novel, potent, selective Kv7 potassium channel opener in Phase 3 clinical trials for epilepsy, major depressive disorder (MDD), and bipolar depression (BPD), alongside early-stage Kv7 and NaV1.7 programs in pain and a NaV1.1 program in Dravet syndrome.
News related to XENE often covers clinical milestones, such as enrollment updates and anticipated topline data from Phase 3 studies like X-TOLE2 and X-TOLE3 in focal onset seizures (FOS), X-ACKT in primary generalized tonic-clonic seizures (PGTCS), and the X-NOVA and X-CEED programs in MDD and BPD. Xenon also issues press releases on long-term X-TOLE open-label extension (OLE) data, which include multi-year seizure frequency reductions and analyses of seizure freedom patterns with extended azetukalner treatment.
Investors and clinicians following XENE can expect scientific conference coverage from meetings such as the American Epilepsy Society Annual Meeting, where Xenon presents posters on epilepsy outcomes, depression burden in epilepsy, and pre-clinical data from its NaV1.1 Dravet syndrome program. Additional news items include corporate updates like quarterly financial results, investor conference presentations, investor webinars, and executive appointments, such as the appointment of a Chief Financial Officer in connection with anticipated commercialization activities.
Bookmark this page to monitor Xenon’s latest announcements on its Phase 3 epilepsy and mood disorder programs, early-stage pain pipeline, partnered work with Neurocrine Biosciences, and ongoing regulatory and investor communications.
Summary not available.
Summary not available.
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) announced its participation at the 2023 American Academy of Neurology (AAN) Annual Meeting, showcasing its XEN1101 epilepsy program. An oral presentation by Dr. Jacqueline French will detail interim results from the open-label extension of the Phase 2b X-TOLE study, highlighting a sustained monthly seizure frequency reduction of 80%-90% from baseline and seizure freedom in 17.5% and 10.5% of patients for ≥6 and ≥12 months, respectively. Additionally, Xenon will present its Phase 3 study, X-ACKT, which evaluates XEN1101 in primary generalized tonic-clonic seizures, aiming for regulatory submissions. The trial will assess the drug's safety and efficacy in approximately 160 patients.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical firm, will present at the 2023 Bloom Burton & Co. Healthcare Investor Conference in Toronto from April 25-26, 2023. The company's presentation is scheduled for April 25, 2023, at 11:00 am Eastern Time (8:00 am Pacific Time). Investors can register for a live webcast of the event here. Ian Mortimer, the President and CEO, will be the presenter. A replay of the webcast will be available on the company's website post-event. Xenon is dedicated to developing innovative therapies for neurological disorders, particularly focusing on epilepsy.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) announced its presentation at the 22nd Annual Needham Virtual Healthcare Conference from April 17-20, 2023. The company will participate in a fireside chat on April 20, 2023, at 2:15 PM ET (11:15 AM PT). Company executives Ian Mortimer (President and CEO) and Sherry Aulin (CFO) will present. Investors can access a live webcast of the presentation on Xenon's website, with a replay available post-event. Xenon focuses on developing innovative therapeutics for neurological disorders, particularly in epilepsy, with a commitment to addressing unmet medical needs.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a biopharmaceutical company focused on neurology, will present at the virtual Stifel 2023 CNS Days on March 28-29, 2023. The presentation will feature Ian Mortimer, President and CEO, and Sherry Aulin, CFO, on March 28 at 1:00 PM Eastern Time (10:00 AM Pacific Time). A live webcast will be available and can be pre-registered for via a provided link. Xenon is dedicated to developing innovative therapies for neurological disorders, particularly epilepsy. For further information, visit www.xenon-pharma.com.
Xenon Pharmaceuticals (NASDAQ:XENE) has advanced its XEN1101 Phase 3 epilepsy program, with ongoing trials including X-TOLE2, X-TOLE3, and X-ACKT. The company expects topline results from the XEN1101 Phase 2 X-NOVA study in major depressive disorder by Q3 2023. Financially, Xenon reported a net loss of $125.4 million for 2022, an increase from $78.9 million in 2021, due to higher R&D and G&A expenses. Cash reserves as of December 31, 2022, were $720.8 million, enough to fund operations until 2026. The company aims to address unmet needs in epilepsy and mental health disorders with its innovative therapies.
Xenon Pharmaceuticals (Nasdaq:XENE) announced it will release its fourth quarter and full year 2022 financial results on March 1, 2023, after U.S. markets close. The company specializes in developing neurology-focused biopharmaceuticals, particularly for epilepsy. A conference call will be held at 4:30 PM ET the same day, with dial-in numbers provided for both domestic and international callers. Additionally, a live audio webcast will be available in the Investors section of their website, offering a replay option post-event.
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) announced its participation in the virtual SVB Securities Global Biopharma Conference from February 14-16, 2023. A key event will be a fireside chat on February 15, 2023, at 3:00 PM ET, featuring Ian Mortimer, President and CEO, and Sherry Aulin, CFO.
A live webcast will be available on their website, with a replay posted after the event. Xenon focuses on developing innovative therapeutics for neurological disorders, particularly epilepsy. More information can be found at www.xenon-pharma.com.
Xenon Pharmaceuticals (NASDAQ:XENE) announced advancements in its XEN1101 Phase 3 epilepsy program, now active in both focal onset seizures and primary generalized tonic clonic seizures. The company is financially robust, expecting to fund its operations until 2026. The X-TOLE2 study for focal seizures is underway, with the newly initiated X-ACKT trial targeting generalized seizures. Data from the X-NOVA study on major depressive disorder is anticipated in Q3 2023, alongside collaboration updates with Neurocrine Biosciences.
FAQ
What is the current stock price of Xenon Pharmaceut (XENE)?
What is the market cap of Xenon Pharmaceut (XENE)?
